- DKK18.31bn
- DKK16.09bn
- DKK6.24bn
Bavarian Nordic in talks with Nordic Capital and Permira on potential takeover
Bavarian Nordic jumps after media report on potential bid
Brief: Bavarian Nordic Confirms Discussion On Potential Takeover
Brief: Bavarian Nordic Gets Acceptance From Health Canada For Review Of New Drug Submission For Chikungunya Vaccine
Brief: Bavarian Nordic Enters Smallpox/Mpox Vaccine Supply Contract With European Country
Valneva rises on vaccines distribution deal in Germany
Brief: Bavarian Nordic Starts Clinical Trials Of Mpox Vaccine In Infants, Pregnant Women
Brief: Bavarian Nordic Announces Sale Of Priority Review Voucher For $160 Mln
Brief: Bavarian Nordic Announces Sale Of Priority Review Voucher For USD 160 Million
Brief: Bavarian Nordic Starts Phase 3 Study Of Chikungunya Vaccine In Children
US CDC accepts recommendations for chikungunya vaccines (updated)
US CDC approves recommendations for chikungunya vaccines
Bavarian Nordic tops STOXX after Q1 revenue beat
Brief: Bavarian Nordic Maintains 2025 Outlook
Kennedy aide and vaccine critic questions recent expert recommendations
Kennedy aide and vaccine critic questions recent expert recommendations
Brief: Bavarian Nordic Wins Contract Options In US For Freeze-dried Smallpox/Mpox Vaccines
Brief: Bavarian Nordic Receives Authorization For Chikungunya Vaccine In UK
Brief: UK's MHRA Approves Vimkunya Vaccine For Chikungunya In People Aged 12 And Older